Curr Psychiatry Rep (2015) 17: 92
DOI 10.1007/s11920-015-0627-4

$GABA_A$ Receptor-Modulating Steroids in Relation to Women's Behavioral Health

Torbjörn Bäckström[1] · **Marie Bixo**[1] · **Jessica Strömberg**[1]

Published online: 23 September 2015

Abstract In certain women, increased negative mood relates to the progesterone metabolite, allopregnanolone (allo), during the luteal phase of ovulatory menstrual cycles, the premenstrual dysphoric disorder (PMDD). In anovulatory cycles, no symptom or sex steroid increase occurs but symptoms return during progesterone/allo treatment. Allo is a potent $GABA_A$ receptor-modulating steroid and as such is expected to be calming and anxiolytic. A relation to negative mood is unexpected. However, this paradoxical effect can be induced by all $GABA_A$ receptor modulators in low concentrations whereas higher concentrations are calming. The severity of the mood symptoms relate to allo in an inverted U-shaped curve at endogenous luteal-phase serum concentrations. Allo's effects on the $GABA_A$ receptor can be antagonized by isoallopregnanolone (ISO), an antagonist to allo. ISO has also been used in a preliminary clinical trial on PMDD ameliorating symptoms with good effect in PMDD patients.

Keywords $GABA_A$ receptor-modulating steroids · Premenstrual dysphoric disorder · Mood symptoms

This article is part of the Topical Collection on *Women's Mental Health*

✉ Torbjörn Bäckström
torbjorn.c.backstrom@umu.se

Marie Bixo
Marie.Bixo@umu.se

Jessica Strömberg
Jessica.Stromberg@umecrine.se

[1] Department of Clinical sciences, Obstetrics and Gynecology, Umeå neurosteroid research center, Umeå University, Building 6M 4th floor, Umeå, Sweden

Introduction

One very obvious relation between steroids in serum and mood symptoms in women is the symptom variations during the menstrual cycle. The sex hormones estradiol and progesterone show regular predictable changes during the menstrual cycle. In parallel with progesterone, the $GABA_A$ receptor-modulating steroids allopregnanolone (allo) and pregnanolone increase in serum [1, 2] and are produced by the corpus luteum of the ovary [3]

Negative Mood Symptoms are Related to $GABA_A$ Receptor-Modulating Steroid Concentrations in Serum

Conditions where there is evidence for the interaction between mood, steroids, and CNS function are the premenstrual dysphoric disorder (PMDD) [4] and the less severe condition premenstrual syndrome (PMS) [5]. In PMDD/PMS, the symptoms develop during the luteal phase of the menstrual cycle [6, 7, 8••]. The symptoms start at the time of ovulation, and the severity increases in parallel with the rise in serum progesterone and it's $GABA_A$ receptor-modulating metabolite allo (Fig. 1). The symptom severity reaches a maximum during the last five premenstrual days or at the first day of menstruation and usually disappears within 3–4 days into the next menstrual cycle. During the postmenstrual phase, there is a period of well-being related to the estradiol peak [8••]. The close relation between the presence of mood symptoms and the steroid production from the corpus luteum of the ovary suggests that there is a symptom-provoking factor produced by the corpus luteum of the ovary. In anovulatory cycles, spontaneous or induced, the corpus luteum is not formed and progesterone or allo is not produced. In such cycles, the premenstrual symptom cyclicity disappears [10, 11••, 12]. We know that the increase in serum concentration due to



Fig. 1 PMDD core symptoms and allopregnanolone concentrations during an idealized menstrual cycle in women with PMDD. Data are centered on the day of menstrual bleeding onset and ovulation. Irritability and depression scores were rated using a Likert rating scale. The symptoms correlate best with allopregnanolone serum concentration with 3 days latency after allopregnanolone curve. From [9], with permission from Elsevier



Fig. 2 Mood changes in postmenopausal women taking sequential hormone replacement therapy in a cross-over double-blind controlled study. Progesterone but not placebo is accompanied with negative mood symptoms. From [16], with permission from Elsevier

production from the corpus luteum is noted in the brain even though the concentration varies depending on the brain region [13]. The regional brain distribution of allopregnanolone showed the highest levels in the substantia nigra, and the basal hypothalamus was significantly higher than in all other investigated areas except the amygdala. Taken together, the brainstem, basal ganglia, and cerebellum showed significantly higher concentrations during the luteal phase compared to postmenopausal controls. The other areas showed numerical differences but did not reach significance probably due to low sample number as only four (4) women were obtained in the respective groups [13]. That the symptom-provoking factor could be progesterone or allo is shown by the fact that the symptoms reappear in PMDD women where the endogenous ovarian steroid production is inhibited, with gonadotropin-releasing hormone agonist treatment (GnRH), but estrogen and progesterone ad back is given. Women with PMDD then develop negative mood symptoms during the progesterone/allo period. Normal control women do not react on the progesterone/allo ad back contrary to women with PMDD [14, 15]. Similar increase in negative mood is noted in postmenopausal women receiving cyclical estrogen progesterone therapy (Fig. 2), [17••]. In the study by Schmidt et al. [14], both estradiol alone and progesterone alone provoked symptoms in anovulatory leuprolide-treated women. This is contrary to results by Segerblad et al. where estrogen-alone treatment was related to a period of well-being [15]. Also in postmenopausal women, estrogen alone is related to periods of well-being while estrogen combined with progesterone gives increased negative mood [16, 18]. During the menstrual cycle in women with PMDD, the period around the preovulatory estradiol peak is a period of well-being, that is, the women feel as best [8••]. However, estrogen in combination with progesterone/allo seems to have a different effect. A higher dosage of estrogen together with progestogen is related to worse symptoms [18], and in a placebo-controlled study, estrogen treatment during the luteal phase worsened the symptoms [19]. The reason why Schmidt and coworkers obtained a worsening of PMDD symptom by estradiol alone is puzzling and has not been repeated in other studies.

Paradoxical Response to Positive $GABA_A$ Receptor-Modulating Steroids

Normally positive $GABA_A$ receptor modulators like benzodiazepines, alcohol, and barbiturates are anxiolytic, induce sedation, calmness, and have antiepileptic effects. Why there is a relation between the luteal-phase increase in allo after ovulation and the development of negative mood is difficult to understand as allo should be anxiolytic like benzodiazepines. The answer seems to be the fact that all positive $GABA_A$ receptor modulators like benzodiazepines, barbiturates, alcohol, and allo have paradoxical anxiogenic effects under certain circumstances in certain individuals. The compounds are not always showing the expected effect but instead induce the opposite effect such as irritability and anxiety. This reaction is called a paradoxical reaction or a paradoxical effect. The paradoxical symptoms induced by these $GABA_A$ receptor-active drugs are irritability, aggression, anxiety, depression, and other symptoms also known to occur during the luteal phase in women with PMDD [4] or PMS [5] and during progestogen treatments in postmenopausal hormone-replacement therapy [16, 20]. For example, certain patients

react to low-dosage benzodiazepines with irritability, aggression, confusion, violence, and impaired impulse control but have a normal anxiolytic calming effect on higher dosages [21–23]. Human reports indicate that strong negative symptoms are induced in 3–6 % of individuals and moderate symptoms in 20–30 % [24, 25]. Interestingly, the prevalence of premenstrual dysphoric disorder among women in reproductive age is in the similar range, 3–8 % [4], and 25–35 % has milder symptom severity in PMS [5, 26]. Weinbroum et al. reported a 10.2 % incidence of paradoxical events to midazolam in patients who underwent surgery during a 3-month period. They showed that benzodiazepine receptor antagonist treatment effectively reversed the paradoxical behaviors [25]. The paradoxical effect can also be induced by barbiturates, e.g., during evaluation of epileptic patients for epilepsy surgery [27, 28]. Alcohol has also been associated with paradoxical effects like increased irritability and aggression. A number of human studies have reported increased aggression after alcohol consumption [29, 30].

Studies on mood effects of oral progesterone treatment show an inverted U-shaped bimodal pattern in the negative mood severity to allo concentration. Postmenopausal women with oral progesterone treatment developed allo concentrations in physiological luteal-phase concentrations and responded with the highest negative mood scores. The mood deterioration is less evident at lower and higher concentrations (Fig. 3), [17••]. In postmenopausal women, the bimodal effect has been noted with different dosages of medroxyprogesterone (MPA) and natural progesterone in hormone-replacement therapy (HRT). The women feel worse on a lower dosage than a higher dosage or placebo [16, 20]. A similar difference between high and low progestogen dosages has also been noted for oral contraceptives [31].



Fig. 3 Negative mood ratings from the same day as blood samples were taken. Symptoms increase related to increasing serum allopregnanolone in postmenopausal women taking oral progesterone. The *shaded area* indicates the normal allopregnanolone range during the luteal phase of the menstrual cycle. From [17••], with permission from Springer

An inverted U-shaped relation between allo, alcohol, and midazolam dosage and irritability/aggression has also been noted in rats [32, 33]. In rats, the benzodiazepine-heightened aggressive behavior induced by midazolam or triazolam was also antagonized by flumazenil and the $GABA_A$ receptor antagonists β-CCt and 3-PBC [33, 34]

Indications of a paradoxical and inverted U-shaped relation between allo and negative mood symptoms is also seen in fMRI studies in women and will therefore be mentioned here. Especially the amygdale has been studied in relation to emotional experiences and is therefore of interest to study. The amygdale responses to fearful and aversive pictures after oral progesterone administration has been studied at moderate and high allo concentrations. Oral progesterone is metabolized to allo in a high degree, and the serum concentration of allo obtained is equal to that of progesterone [35]. Administration of progesterone, giving plasma concentrations in the upper luteal-phase range as when the negative mood symptom in patients are highest, increases the neural response to angry and fearful faces in the amygdale compared to placebo [36••]. A reduced fMRI response would be expected together with an anxiolytic effect similar to the benzodiazepine response in dosages giving anxiolytic effects. Benzodiazepines giving an anxiolytic effect also give reduced fMRI responses to angry and fearful face stimuli [37]. However, even higher allo concentrations, in the pharmacological sedative and late pregnancy range, are associated with a decrease in amygdale reactivity similar to the benzodiazepine fMRI effect when anxiolysis is induced. It seems as if allo at this concentration has passed the peak of the paradoxical effect and the concentration is in the anxiolytic range. The opposite responses in amygdala at low compared to high allo concentrations support the hypothesis of a bimodal paradoxical effect of allo [38••]. The increased amygdale response in the fMRI studies was observed when allo levels were in the luteal phase or early pregnancy range [1, 39], whereas higher concentrations gave a different response [38••].

Sensitivity in the $GABA_A$ System to Different $GABA_A$ Modulators in PMDD

It seems thus that a subset of individuals is very sensitive to low doses or concentrations of allo and responds with severe adverse emotional reactions when provoked. There are now increasing neuroimaging data available on menstrual cycle and sex steroid influence on brain activity under normal physiological situations and in disorders. An excellent review of studies on PMDD/PMS is available elsewhere, and that topic is over the scope of this review [40]. There is evidence that the sensitivity in the brain for steroids differs between PMS/PMDD patients and controls. Saccadic eye velocity (SEV) recorded by electrooculography is a measurement of functional $GABA_A$ receptor activity, and the method could be used in challenges with different $GABA_A$ receptor modulators [41].

In patients with PMDD, a decreased sensitivity to diazepam but an increased sensitivity to allo has been shown in the SEV model. In studies on women with PMDD and controls, relapse of symptoms did not occur in normal women or in PMS/PMDD women during placebo treatment, but the symptoms appear during the progestogen treatment in women with PMDD [15]. Neuroimaging studies show different responses in women with PMDD compared to women without any menstrual-cycle-related mood changes [42, 43].

In PMS/PMDD patients but not in healthy controls, SEV and the sedative response to intravenous diazepam and alcohol is reduced in the luteal phase compared to follicular phase [44–46]. In addition, patients with severe symptoms were less sensitive to the given pregnanolone or benzodiazepine compared to patients with more moderate symptoms [44, 47].

Possible Treatments Related to the GABA-Hypothesis

As has been mentioned above, allo seems to be involved in the induction of negative mood symptoms in women with PMDD. If the hypothesis is correct, a blockade of the allo effects on the $GABA_A$ receptor should be a possible treatment of PMDD. Studies of allo in vitro on the $GABA_A$ receptor activity and in vivo animal studies of sedation have shown that allo-induced effects can be inhibited by isoallopregnanolone (ISO) which also is an endogenous steroid isomer of allo [48–50]. In an experimental study, we have investigated if ISO can antagonize allo-induced CNS effects in healthy female volunteers, by using measurements of SEV and self-rated sedation. Healthy women were studied on three separate occasions, after being given allo alone or allo in combination with one of two ISO doses. Allo administration decreased SEV and induced sedation as expected, and these effects were diminished by simultaneous ISO administration. The ISO effect seems also to be stronger for SEV than for sedation [51••]. These effects were observed already at an ISO dose exposure that was approximately half of that of allo. In a recently performed, double-blind placebo controlled clinical trial using ISO as treatment for PMDD, preliminary data show a significant amelioration of PMDD symptoms compared to placebo in women with PMDD [52].

ISO is a 3beta-hydroxy isomer of allo and is also an endogenous steroid. ISO has no effect by itself on the $GABA_A$ receptor or on any of the steroid hormonal receptors [48, 49, 53]. The endogenous concentrations of ISO in normal women vary with the menstrual cycle and are about four times higher during mid-luteal phase (1.23±1.12 mean±SD, nanomol/L) compared to the follicular phase. The concentration of ISO both in the follicular and luteal phases is about half (54–57 %) the concentration of allo [54], but there are no ISO concentrations measured in patients with PMDD. In women with chronic fatigue syndrome, both allo and ISO are increased in the serum but the increase of ISO was greater than for allo; one speculative explanation is that ISO is increased to compensate for the increased sedative effect of allo [55]. There is also a study on depressed patients, mixed sexes, and menstrual cycle phases. The results are difficult to interpret, but ISO seems to be increased while allo seems not to be increased [56]

Other Behavioral Health Conditions Common in Women and Related to $GABA_A$ Modulating Steroids, e.g., Burnout Syndrome and Post-Traumatic Stress Disorder (PTSD)

As mentioned above, low concentrations or doses of positive $GABA_A$ receptor modulators give severe adverse emotional reactions in a subset of individuals (3–6 %) and moderate reactions in up to 20–30 %. In PMDD/PMS, the symptoms are known to occur during the luteal phase in women. However, allo is also always de novo synthesized in the central nervous system, and the CNS production is regulated differently from the gonadal and adrenal production [13, 57]. Changes in the CNS production have implications for the GABAergic function in the brain [58]. This suggests that there can be other CNS-related conditions that are influenced by allo. We have studied women with burnout syndrome, and they show an increased sensitivity to allo compared to healthy controls [59]. Women with post-traumatic stress syndrome are, however, less sensitive to allo than healthy controls and also less sensitive to benzodiazepine challenge suggesting that they have a changed $GABA_A$ receptor function which is different from women with burnout syndrome [60].

There are indications that early life emotional trauma is related to an increased risk of developing PMDD/PMS [61]. Early life stress history is also a risk factor for developing PTSD after a trauma later in life [62]. Women developing PTSD after a rape show a decreased sensitivity to benzodiazepines. PMS/PMDD patients and panic disorder patients are also less sensitive to benzodiazepines [45, 60, 63] suggesting that there might be a common $GABA_A$ receptor change in these three disorders.

Conclusion

Here we give some evidence and examples on mental effects induced by $GABA_A$ receptor-modulating steroids. This is a new mechanism and field of mechanisms in especially women's mental health and behavior. Interesting is that treatments for these disorders induced by $GABA_A$ receptor-active compounds is on the way, and a new area for treatments of mental disorders opens up, however, not only in women but also in men.

Acknowledgments The work that led to this review was supported by grants from the Swedish Research Council, medicine proj. 4X-11198, Västerbottensl läns landsting centrala ALF and spjutspets, Umecrine Mood AB, and Umeå University foundations.

Compliance with Ethics Guidelines

Conflict of Interest Torbjörn Bäckström is a share holder in Umecrine AB.

Marie Bixo has nothing to declare.

Jessica Strömberg has nothing to declare.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

•• Of major importance

1. Nyberg S, Backstrom T, Zingmark E, Purdy RH, Poromaa IS. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. Gynecol Endocrinol. 2007;23(5):257–66.
2. Innala E, Backstrom T, Poromaa IS, Andersson C, Bixo M. Women with acute intermittent porphyria have a defect in 5alpha-steroid production during the menstrual cycle. Acta Obstet Gynecol Scand. 2012;91(12):1445–52.
3. Ottander U, Poromaa IS, Bjurulf E, Skytt A, Bäckström T, Olofsson JI. Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol Cell Endocrinol. 2005;239(1-2):37–44.
4. American Psychiatric Association D-, Diagnostic and statistical manual of mental disorders (DSM-5). 2013: American Psychiatric Publishing.
5. ACOG American College of Obstetricians and Gynecologists, ACOG practice bulletin. Premenstrual syndrome. nternational Journal of Gynecology & Obstetrics. 2001;73:183–191.
6. Nevatte T, O'Brien PMS, Backstrom T, Brown C, Dennerstein L, Endicott J, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16(4):279–91.
7. Sundstrom Poromaa I, Gingnell M. Menstrual cycle influence on cognitive function and emotion processing-from a reproductive perspective. Front Neurosci. 2014;8:380.
8.•• Backstrom T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med. 1983;45(6):503–7. **This shows that symptoms are closely related to the allopregnanolone concentrations in serum**.
9. Backstrom T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. Allopregnanolone and mood disorders. Prog Neurobiol. 2014;113:88–94.
10. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67(2):159–66.
11.•• Hammarback S, Ekholm UB, Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh). 1991;125(2):132–7. **This shows that cyclocal symptoms in PMDD disappears in anovulatory cycles when allopregnanolone is not formed**.
12. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991;72(2):252A–F.
13. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997;764(1-2):173–8.
14. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209–16.
15. Segebladh B, Borgstrom A, Nyberg S, Bixo M, Sundstrom-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol. 2009;201(2)):139–e1-8.
16. Andreen L, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology. 2005;30(2):212–24.
17.•• Andreen L, Sundstrom-Poromaa I, Bixo M, Andersson A, Nyberg S, Backstrom T. Allopregnanolone concentration and mood–a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl). 2006;187(2):209–21. **PMDD like symptoms appear when postmenopausal women are treated with progesterone/allopregnanolone as HRT indicating that it is progesterone/allopregnanolone that causes the symptoms**.
18. Bjorn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab. 2003;88(5):2026–30.
19. Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology. 1990;15(5-6):489–93.
20. Bjorn I, Bixo M, Nojd KS, Collberg P, Nyberg S, Sundstrom-Poromaa I, Backstrom T. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol. 2002;16(1):1–8.
21. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol. 1981;11 Suppl 1:99S–04S.
22. Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc. 1994;40(1):86–8.
23. Ben-Porath DD, Taylor SP. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. Addict Behav. 2002;27(2):167–77.
24. Masia SL, Perrine K, Westbrook L, Alper K, Devinsky O. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology. 2000;54(8):1691–3.
25. Weinbroum AA, Szold O, Ogorek D, Flaishon R. The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol. 2001;18(12):789–97.
26. Sveindottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2000;79(5):405–13.
27. Kurthen M, Linke DB, Reuter BM, Hufnagel A, Elger CE. Severe negative emotional reactions in intracarotid sodium amytal

procedures: further evidence for hemispheric asymmetries? Cortex. 1991;27(2):333–7.
28. Lee GP, Loring DW, Meador KJ, Flanigin HF, Brooks BS. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology. 1988;38(8):1233–6.
29. Cherek DR, Spiga R, Egli M. Effects of response requirement and alcohol on human aggressive responding. J Exp Anal Behav. 1992;58(3):577–87.
30. Dougherty DM, Cherek DR, Bennett RH. The effects of alcohol on the aggressive responding of women. J Stud Alcohol. 1996;57(2): 178–86.
31. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with placebo. Acta Psychiat Scand, 1972; 236(Suppl.):1-84
32. Miczek KA, Fish EW, De Bold JF. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav. 2003;44(3): 242–57.
33. Gourley SL, Debold JF, Yin W, Cook J, Miczek KA. Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists. Psychopharmacol (Berl). 2005;178(2-3):232–40.
34. Weerts EM, Tornatzky W, Miczek KA. "Anxiolytic" and "anxiogenic" benzodiazepines and beta-carbolines: effects on aggressive and social behavior in rats and squirrel monkeys. Psychopharmacol (Berl). 1993;110(4):451–9.
35. Andreen L, Spigset O, Andersson A, Nyberg S, Backstrom T. Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone. Maturitas. 2006;54(3):238–44.
36.•• van Wingen GA, van Broekhoven F, Verkes RJ, Petersson KM, Backstrom T, Buitelaar JK, et al. Progesterone selectively increases amygdala reactivity in women. Mol Psychiatry. 2008;13(3):325–33. **This shows the paradoxical effect of progesterone/allopregnanolone on amygdala response to aversive pictures**.
37. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry. 2005;62(3):282–8.
38.•• van Wingen G, van Broekhoven F, Verkes RJ, Petersson KM, Backstrom T, Buitelaar J, et al. How progesterone impairs memory for biologically salient stimuli in healthy young women. J Neurosci. 2007;27(42):11416–23. **This shows the paradoxical effect of progesterone/allopregnanolone on amygdala response to aversive pictures**.
39. Parizek A, Hill M, Kancheva R, Havlikova H, Kancheva L, Cindr J, et al. Neuroactive pregnanolone isomers during pregnancy. J Clin Endocrinol Metab. 2005;90(1):395–403.
40. Toffoletto S, Lanzenberger R, Gingnell M, Sundstrom-Poromaa I, Comasco E. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology. 2014;50:28–52.
41. Backstrom T, Andersson A, Andree L, Birzniece V, Bixo M, Bjorn I, et al. Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci. 2003;1007:42–53.
42. Gingnell M, Ahlstedt V, Bannbers E, Wikstrom J, Sundstrom-Poromaa I, Fredrikson M. Social stimulation and corticolimbic reactivity in premenstrual dysphoric disorder: a preliminary study. Biol Mood Anxiety Disord. 2014;4(1):3.
43. Protopopescu X, Tuescher O, Pan H, Epstein J, Root J, Chang L, et al. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J Affect Disord. 2008;108(1-2):87–94.
44. Sundstrom I, Nyberg S, Backstrom T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology. 1997;17(6): 370–81.
45. Sundstrom I, Ashbrook D, Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology. 1997;22(1):25–38.
46. Nyberg S, Wahlstrom G, Backstrom T, Sundstrom Poromaa I. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology. 2004;29(6):767–77.
47. Sundstrom I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology. 1998;67(2):126–38.
48. Lundgren P, Stromberg J, Backstrom T, Wang M. Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3beta-hydroxy-5alpha-pregnan-20-one (isoallopregnanolone). Brain Res. 2003;982(1):45–53.
49. Wang MD, Backstrom T, Landgren S. The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol Scand. 2000;169(4):333–41.
50. Backstrom T, Wahlstrom G, Wahlstrom K, Zhu D, Wang MD. Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. Eur J Pharmacol. 2005;512(1):15–21.
51.•• Bengtsson SK, Nyberg S, Hedstrom H, Zingmark E, Jonsson B, Backstrom T, et al. Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology. 2015;52:22–31. **This shows that the effect of allopregnanolone on sedation and saccadic eye velocity can be inhibited by isoallopregnanolone**.
52. Bixo M. Biomarkers for premenstrual dysphoric disorder. GABAA modulating steroid antagonists -a possible treatment for premenstrual dysphoric disorder. . in 44th Annual Meeting of the International Society of Psychoneuroendocrinology, 19th-22nd August. 2014. Montreal, Canada.
53. Stromberg J, Haage D, Taube M, Backstrom T, Lundgren P. Neurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor. Neuroscience. 2006;143(1):73–81.
54. Havlikova H, Hill M, Kancheva L, Vrbikova J, Pouzar V, Cerny I, et al. Serum profiles of free and conjugated neuroactive pregnanolone isomers in nonpregnant women of fertile age. J Clin Endocrinol Metab. 2006;91(8):3092–9.
55. Murphy BE, Abbott FV, Allison CM, Watts C, Ghadirian AM. Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome. Psychoneuroendocrinology. 2004;29(2):245–68.
56. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry. 1998;155(7):910–3.
57. Cheney DL, Uzunov D, Costa E, Guidotti A. Gas chromatographic-mass fragmentographic quantitation of 3 alpha-hydroxy-5 alpha-pregnan-20-one (allopregnanolone) and its precursors in blood and brain of adrenalectomized and castrated rats. J Neurosci. 1995;15(6):4641–50.
58. Puia G, Mienville JM, Matsumoto K, Takahata H, Watanabe H, Costa E, et al. On the putative physiological role of allopregnanolone on GABA(A) receptor function. Neuropharmacology. 2003;44(1):49–55.
59. Holmberg E, Backstrom T, Johansson M, Lofgren M, Haage D. Allopregnanolone induces a diurnally dependent hyperphagic effect and alters feeding latency and duration in male Wistar rats. Acta Physiol (Oxf). 2013;208(4):400–9.

60. Moller AT, Backstrom T, Nyberg S, Sondergaard HP, Helstrom L. Women with PTSD have a changed sensitivity to GABA-A receptor active substances. Psychopharmacology (Berl). 2014.
61. Bertone-Johnson ER, Whitcomb BW, Missmer SA, Manson JE, Hankinson SE, Rich-Edwards JW. Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study. J Womens Health (Larchmt). 2014;23(9):729–39.
62. Breslau N, Chilcoat HD, Kessler RC, Davis GC. Previous exposure to trauma and PTSD effects of subsequent trauma: results from the Detroit Area Survey of Trauma. Am J Psychiatry. 1999;156(6): 902–7.
63. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47(6):534–8.